As of Feb 21, 2025, Novo Nordisk A/S Intrinsic Value is $60.9. This suggests it may be overvalued by 30.9% compared to its current price of around $88.1.

What is Novo Nordisk A/S DCF (discounted cash flow) valuation?

As of Feb 21, 2025, Novo Nordisk A/S's Discounted Cash Flow (DCF) valuation estimates its share price at $79.0. This suggests it may be overvalued by 10.3% to its current price of around $88.1, using a discount rate of 7.4% and terminal growth rate of 3.0%.

Is Novo Nordisk A/S overvalued or undervalued?

Novo Nordisk A/S is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $60.9, compared to a market price of around $88.1. This suggests a potential overvaluation of 30.9%.